Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
1 hedge funds and large institutions have $9 invested in Sage Therapeutics in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less capital invested
Capital invested by funds: $460K → $9 (-$460K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$460K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HNB
1
Huntington National Bank
Columbus,
Ohio
| $9 | – | – | – |
|
|
2
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$460K | -22,220 | Closed |
|
SAGE Hedge Fund Activity: Q1 2026 in Review
1 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2026, worth a combined $9 — down 100% from $460K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SAGE and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $460K sold.
- 1 institutional investor held Sage Therapeutics (SAGE) as of Q1 2026, down from 2 in Q4 2025.
- Funds reported $9 of Sage Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Sage Therapeutics positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest Sage Therapeutics seller in Q1 2026 was DekaBank Deutsche Girozentrale, an estimated $460K sold.
Based on aggregated 13F filings for Q1 2026.